免疫療法研究(Immunotherapy Research) 活體用重組抗體
針對治療研究，抗蛋白質的抗體參與co-stimulation和免疫系統調節(immune cell regulation)。 有些進入臨床階段(clinic)；更多部份仍處於研究階段。免疫細胞信號傳導(immune cell signaling)的許多方面仍然未知，Absolute Antibody開發了針對臨床相關蛋白的重組工程抗體，提供一系列免疫療法研究(Immunotherapy Research) 活體用重組抗體。
• Your favourite research tools, now updated through antibody engineering for improved performance in vivo
• Reduce immunogenicity by matching antibody species to your host organism
• Tailor effector function by choosing from our range of antibody isotypes and subtypes
• Explore new possibilities by combining two of these antibodies into a custom bispecific reagent

Anti-PD-1H [MH5A], Mouse IgG2a, Fc Silent™, Lambda抗體 | 貨號Ab01016-2.3

抗體介紹: 此抗體特異性針對PD-1H抗原。The antibody has been labelled with biotin and used to stain formalin-fixed tissues from wild-type C57BL/6 mice at 6 weeks of age. This showed specific staining for PD-1H in the T cell zone and marginal zone. The antibody stains P815 cells transfected with full-length PD-1H plasmid, but not control plasmid. Antibody specificity has been confirmed by ELISA. A single 200-μg dose of MH5A prevented aGVHD in mouse models, caused a reduction in accumulation and expansion of CD8+ and CD4+ T cells in spleens and livers and greatly reduced numbers of inflitrating T cells in all aGVHD target tissues examined. Few mAbs targeting a single cosignalling molecule have such a potent preventative effect (Flies D et al, 2011).。可應用於therapeutic, Block, ELISA, IHC等實驗。Species Reactivity: Mouse

Immunofluorescence staining of fixed mouse splenocytes with anti-PD-1H antibody MH5A (Ab01016) Immunofluorescence analysis of paraformaldehyde fixed mouse splenocytes permeabilized with 0.15% Triton and stained with the chimeric mouse IgG1 version of MH5A (Ab01016-23.0) at 10 µg/ml for 1h followed by Alexa Fluor® 488 secondary antibody (2 µg/ml), showing membrane staining. The nuclear stain is DAPI (blue). Panels show from left-right, top-bottom Ab01016-23.0, DAPI, merged channels and an isotype control. The isotype control was stained with an anti-unknown specificity antibody (Ab178-23.0) followed by Alexa Fluor® 488 secondary antibody.

ELISA of anti-VISTA antibody on VISTA-Fc fusion protein. Binding curve of the rabbit chimeric version of the anti-VISTA antibody MH5A (Ab01016-23.0; blue line) to an ELISA plate coated with mouse VISTA-Fc fusion protein (Pr00164-1.9) at a concentration of 5 µg/ml. A 3-fold serial dilution from 10000 to 1.7 ng/ml was performed using Ab01016-23.0. For signal detection, a 1:4000 dilution of anti-rabbit IgG1 HRP (BioRad) antibody was used.

Purified antibody.
Purification: Protein A affinity purified
Supplied in: PBS with 0.02% Proclin 300.
Storage Recommendation: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Concentration: 1 mg/ml.

UniProt Accession Number of Target Protein: Q9D659

Alternative Name(s) of Target: VISTA; VISR; B7-H5; B7H5; GI24; PP2135; SISP1; DD1alpha; C10orf54; chromosome 10 open reading frame 54; V-set immunoregulatory receptor
Immunogen: The antibody was generated by immunising Armenian hamsters with mPD-1HIg.

Specificity: This antibody specifically binds PD-1H.

Application Notes: The antibody has been labelled with biotin and used to stain formalin-fixed tissues from wild-type C57BL/6 mice at 6 weeks of age. This showed specific staining for PD-1H in the T cell zone and marginal zone. The antibody stains P815 cells transfected with full-length PD-1H plasmid, but not control plasmid. Antibody specificity has been confirmed by ELISA. A single 200-μg dose of MH5A prevented aGVHD in mouse models, caused a reduction in accumulation and expansion of CD8+ and CD4+ T cells in spleens and livers and greatly reduced numbers of inflitrating T cells in all aGVHD target tissues examined. Few mAbs targeting a single cosignalling molecule have such a potent preventative effect (Flies D et al, 2011).

Antibody first published in: Flies D et al. Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models J Immunol August 15, 2011, 187 (4) 1537-1541 PMID:21768399
Note on publication: Describes the generation of the antibody and characterisation of its theraputic function in models of graft-versus-host disease.